AIP and the somatostatin system in pituitary tumours.

Abstract

Classic somatostatin analogues aimed at somatostatin receptor type 2, such as octreotide and lanreotide, represent the mainstay of medical treatment for acromegaly. These agents have the potential to decrease hormone secretion and reduce tumour size. Patients with a germline mutation in the aryl hydrocarbon receptor-interacting protein gene, AIP, develop young-onset acromegaly, poorly responsive to pharmacological therapy. In this review, we summarise the most recent studies on AIP-related pituitary adenomas, paying special attention to the causes of somatostatin resistance; the somatostatin receptor profile including type 2, type 5 and truncated variants; the role of G proteins in this pathology; the use of first and second generation somatostatin analogues; and the role of ZAC1, a zinc-finger protein with expression linked to AIP in somatotrophinoma models and acting as a key mediator of octreotide response.

• Authors: Alejandro Ibáñez-Costa, Márta Korbonits
• Journal: The Journal of endocrinology (J Endocrinol) Vol. 235 Issue 3 Pg. R101-R116 (Dec 2017) ISSN: 1479-6805 [Electronic] England
• PMID: 28835453 (Publication Type: Journal Article, Review)
• Copyright: © 2017 Society for Endocrinology.

Chemical References

• Intracellular Signaling Peptides and Proteins
• aryl hydrocarbon receptor-interacting protein
• Somatostatin

Topics

• Adenoma (metabolism)
• Gene Expression Regulation, Neoplastic (physiology)
• Humans
• Intracellular Signaling Peptides and Proteins (genetics, metabolism)
• Pituitary Neoplasms (metabolism)
• Somatostatin (metabolism)